Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptose Biosciences Inc.APTO · Entity 33387 | Executive VP & CFO | January 04, 2021 | January 06, 2021 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | CFO | June 02, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptose Biosciences Inc.
Report date January 04, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2031-01-04 | Direct | 343,000 |
Reported balance
After 2021-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 343,000 · Balance 343,000 F1: The options were granted on January 4, 2021. One-half of the options vest on January 4, 2022. The remaining one-half of the options vest as follows: 1/3 on January 4, 2023; 1/3 on January 4, 2024; and 1/3 on January 4, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on January 4, 2021. One-half of the options vest on January 4, 2022. The remaining one-half of the options vest as follows: 1/3 on January 4, 2023; 1/3 on January 4, 2024; and 1/3 on January 4, 2025.
SUTRO BIOPHARMA, INC.
Report date June 02, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,725 |
Reported balance
After 2026-06-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 2,500 · Balance 4,725 F1: For avoidance of doubt, the reporting person elected to satisfy tax withholding liabilities in cash in lieu of withholding shares. F2: The reported total includes 250 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its employee stock purchase plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2029-06-02 | Direct | 7,500 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 2,500 · Balance 7,500 F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4: The award vested or vests annually as to 1/4th of the total award, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: For avoidance of doubt, the reporting person elected to satisfy tax withholding liabilities in cash in lieu of withholding shares.
F2: The reported total includes 250 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its employee stock purchase plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F4: The award vested or vests annually as to 1/4th of the total award, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on June 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 2, 2026 20:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001761333-26-000005 · form4-06022026_080600.xml · derivative · entry 2 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests annually as to 1/4th of the total award, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 2, 2026 20:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001761333-26-000005 · form4-06022026_080600.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: For avoidance of doubt, the reporting person elected to satisfy tax withholding liabilities in cash in lieu of withholding shares. F2 · balance_after: The reported total includes 250 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its employee stock purchase plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001761333-26-000002 · form4-03032026_110348.xml · derivative · entry 2 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total award annually, with the first tranche vesting on March 1, 2027, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001761333-26-000002 · form4-03032026_110348.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-03-02 F1 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service through each vesting date, with the first tranche vesting on April 1, 2026. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 21:47 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001761333-25-000008 · form4-12292025_091238.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2035-12-23 F1 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 12:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 19,750 | $0.81 | $15,997.50 |
DisclosureSEC source: 0001761333-25-000005 · form4-10162025_121041.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8099 to $0.8100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 2, 2025 20:27 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015142 · form4-06022025_080648.xml · derivative · entry 2 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests annually as to 1/4th of the total award beginning on June 2, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 02, 2025 Filed Jun 2, 2025 20:27 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001415889-25-015142 · form4-06022025_080648.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-06-02 F1 · derivative.exercise_date: 25% of the option award vests on June 2, 2026. The remainder vests ratably as to 1/48th of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:02 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Option (Right to Buy) · Derivative | 343,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001567619-21-000611 · doc1.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,000 Underlying: Common Shares · 343,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were granted on January 4, 2021. One-half of the options vest on January 4, 2022. The remaining one-half of the options vest as follows: 1/3 on January 4, 2023; 1/3 on January 4, 2024; and 1/3 on January 4, 2025. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 22:57 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | SaleCommon Shares | 126,668 | $6.05 | $766,341.40 |
DisclosureSEC source: 0001567619-20-013189 · doc1.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,846 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 225,000 restricted stock units, previously reported on a Form 4/A filed with the Securities and Exchange Commission on March 10, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:37 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006195 · doc1.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,514 F1 · shares: Restricted stock units which shall vest on June 10, 2020. Read SEC document |
| March 10, 2020 Filed May 7, 2020 21:15 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009229 · doc1.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,514 F1 · shares: Restricted stock units previously granted with original vesting date of June 10, 2020, shall now vest on July 10, 2020. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 02:41 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Option Grant · Derivative | 1,200,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001567619-20-001978 · doc1.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Shares · 1,200,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on 1/31/2021; the remaining 50% vest as follows: 1/3 on 1/31/2022; 1/3 on 1/31/2023; and 1/3 on 1/31/2024. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 18:03 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 7,500 | $1.84 | $13,815.00 |
DisclosureSEC source: 0001567619-19-013037 · doc1.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · Senior VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,514 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:32 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 5,000 | $1.79 | $8,928.00 |
DisclosureSEC source: 0001567619-19-006894 · doc1.xml · nonDerivative · entry 2 Chow Gregory K. · CIK 0001761333 · Senior VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,014 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.779 to $1.79, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:32 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 10,000 | $1.74 | $17,394.00 |
DisclosureSEC source: 0001567619-19-006894 · doc1.xml · nonDerivative · entry 1 Chow Gregory K. · CIK 0001761333 · Senior VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,014 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.735 to $1.74, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:01 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001567619-19-000417 · doc1.xml · derivative · entry 1 Chow Gregory K. · CIK 0001761333 · Senior VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The options vest as follows: 50% on the first anniversary of the grant with the remaining 50% to vest as follows: 1/3 on the second anniversary of the grant; 1/3 on the third anniversary of the grant; and 1/3 on the fourth anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.